iVeena Entered into a License Agreement with Glaukos to Develop and Commercialize IVMED-80 for keratoconus
Shots:
- iVeena to receive $10M up front & is eligible to receive development and sales milestones along with royalties on sales and will be responsible for all costs associated with the development and regulatory activities on IVMED-80
- Under the terms of the agreement, Glaukos gets an exclusive global license to develop and commercialize IVMED-80 for the treatment of keratoconus
- In a 6mos. P-I/IIa study, IVMED-80 met its 1EPs & showed a reduction in baseline-adjusted Kmax of 1.0 D over PBO. iVeena is also developing IVMED-85, an investigational eyedrop formulation for pediatric myopia while the first human clinical trial is expected to be initiated in early 2023
Ref: Businesswire | Image: iVeena
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
